GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Canopy Growth Corp (NAS:CGC) » Definitions » ROE %

Canopy Growth (Canopy Growth) ROE % : -134.71% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Canopy Growth ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Canopy Growth's annualized net income for the quarter that ended in Dec. 2023 was $-646.4 Mil. Canopy Growth's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $479.8 Mil. Therefore, Canopy Growth's annualized ROE % for the quarter that ended in Dec. 2023 was -134.71%.

The historical rank and industry rank for Canopy Growth's ROE % or its related term are showing as below:

CGC' s ROE % Range Over the Past 10 Years
Min: -151   Med: -15.57   Max: -1.97
Current: -139.35

During the past 13 years, Canopy Growth's highest ROE % was -1.97%. The lowest was -151.00%. And the median was -15.57%.

CGC's ROE % is ranked worse than
93.5% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.385 vs CGC: -139.35

Canopy Growth ROE % Historical Data

The historical data trend for Canopy Growth's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canopy Growth ROE % Chart

Canopy Growth Annual Data
Trend Jul13 Dec14 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.46 -22.09 -44.28 -8.75 -141.56

Canopy Growth Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.38 -233.36 -19.27 -153.96 -134.71

Competitive Comparison of Canopy Growth's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Canopy Growth's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's ROE % distribution charts can be found below:

* The bar in red indicates where Canopy Growth's ROE % falls into.



Canopy Growth ROE % Calculation

Canopy Growth's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=-2395.789/( (2830.627+554.29)/ 2 )
=-2395.789/1692.4585
=-141.56 %

Canopy Growth's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-646.384/( (553.784+405.877)/ 2 )
=-646.384/479.8305
=-134.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Canopy Growth  (NAS:CGC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-646.384/479.8305
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-646.384 / 234.064)*(234.064 / 1123.2095)*(1123.2095 / 479.8305)
=Net Margin %*Asset Turnover*Equity Multiplier
=-276.16 %*0.2084*2.3408
=ROA %*Equity Multiplier
=-57.55 %*2.3408
=-134.71 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-646.384/479.8305
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-646.384 / -689.784) * (-689.784 / -74.304) * (-74.304 / 234.064) * (234.064 / 1123.2095) * (1123.2095 / 479.8305)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9371 * 9.2833 * -31.75 % * 0.2084 * 2.3408
=-134.71 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Canopy Growth ROE % Related Terms

Thank you for viewing the detailed overview of Canopy Growth's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Canopy Growth (Canopy Growth) Business Description

Traded in Other Exchanges
Address
1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include sports drink BioSteel, skincare products under This Works, Martha Stewart CBD, and Storz & Bickel vaporizers. Canopy growth is attempting to merge its U.S. assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
Executives
Theresa Yanofsky director 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
David Angelo Lazzarato director 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Judy Schmeling director C/O HSN, INC., 1 HSN DRIVE, ST.PETERSBURG FL 33729
Hong Judy Eun Joo officer: See Remarks 1 HERSHEY DRIVE, SMITHS FALLS Z4 K7A 0A8
David Eric Klein director, officer: Chief Executive Officer 207 HIGH POINT DRIVE, VICTOR NY 14564
Thomas Carlton Stewart officer: See Remarks 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Christelle Gedeon officer: See Remarks 3 HOLLYHOCK COURT, TORONTO Z4 M3B 0B4
Garth Hankinson director C/O CONSTELLATION BRANDS, INC., 207 HIGH POINT DRIVE, BLDG. 100, VICTOR NY 14564
Greenstar Ii Holdings Llc 10 percent owner 207 HIGH POINT DRIVE, BUILDING 100, VICTOR NY 14564
Greenstar Ii Llc 10 percent owner 207 HIGH POINT DRIVE, BUILDING 100, VICTOR NY 14564
Rade Nikola Kovacevic officer: President 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Phillip Stephen Shaer officer: Chief Legal Officer 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Grant Julious C. Jr officer: Chief Commercial Officer 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8
Sabia James A. Jr. director C/O CONSTELLATION BRANDS, INC., 207 HIGH POINT DRIVE, BLDG. 100, VICTOR NY 14564
Tomas Iv Shipley officer: See Remarks 1 HERSHEY DRIVE, SMITHS FALLS A6 K7A 0A8